Home » Stocks » APRE

Aprea Therapeutics, Inc. (APRE)

Stock Price: $4.05 USD -0.02 (-0.49%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $4.00 -0.05 (-1.24%) May 13, 7:48 PM
Market Cap 86.23M
Revenue (ttm) n/a
Net Income (ttm) -53.75M
Shares Out 21.19M
EPS (ttm) -26.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $4.05
Previous Close $4.07
Change ($) -0.02
Change (%) -0.49%
Day's Open 4.09
Day's Range 3.88 - 4.13
Day's Volume 563,710
52-Week Range 3.88 - 41.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the muta...

1 week ago - GlobeNewsWire

BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mu...

3 weeks ago - GlobeNewsWire

STOCKHOLM, SWEDEN – April 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Aprea Therap...

1 month ago - GlobeNewsWire

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mu...

1 month ago - GlobeNewsWire

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading higher after the company announced that it received FDA Orphan Drug Designation for its eprenetapopt for the treatment of acute myeloid leukemia....

Other stocks mentioned: IMMP
1 month ago - Benzinga

BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mu...

1 month ago - GlobeNewsWire

Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago - Zacks Investment Research

Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 months ago - Zacks Investment Research

BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...

4 months ago - GlobeNewsWire

Aprea (APRE) down as late-stage study on lead candidate, eprenetapopt, combined with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS) fails.

4 months ago - Zacks Investment Research

Aprea Therapeutics Inc. (NASDAQ: APRE) stock was absolutely crushed to start out the week after the company announced results from its late-stage trial evaluating the safety and efficacy of its treatmen...

4 months ago - 24/7 Wall Street

BOSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...

4 months ago - GlobeNewsWire

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...

5 months ago - GlobeNewsWire

Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.

Other stocks mentioned: VKTX, VXRT
5 months ago - The Motley Fool

BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...

5 months ago - GlobeNewsWire

BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...

6 months ago - GlobeNewsWire

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tu...

6 months ago - GlobeNewsWire

BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tu...

6 months ago - GlobeNewsWire

BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactiv...

7 months ago - GlobeNewsWire

BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reac...

7 months ago - GlobeNewsWire

BOSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate muta...

8 months ago - GlobeNewsWire

BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutan...

9 months ago - GlobeNewsWire

Aprea Therapeutics Cancer Therapy Platform Is Promising

9 months ago - Seeking Alpha

Karolinska Development’s portfolio company Aprea Therapeutics expands clinical trial of eprenetapopt for TP53 mutant Acute Myeloid Leukemia

9 months ago - GlobeNewsWire

BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutan...

9 months ago - GlobeNewsWire

Aprea Therapeutics (APRE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

These companies offer promising pipelines that could deliver in the long term.

Other stocks mentioned: ATRA
10 months ago - The Motley Fool

BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that react...

10 months ago - GlobeNewsWire

BOSTON, June 12, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutan...

11 months ago - GlobeNewsWire

Aprea Therapeutics (APRE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

Here's why this biotech company with a promising treatment for a rare blood disorder is a solid buy.

11 months ago - The Motley Fool

BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutan...

11 months ago - GlobeNewsWire

BOSTON, May 15, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant...

11 months ago - GlobeNewsWire

Aprea Therapeutics (APRE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

BOSTON, April 06, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant...

1 year ago - GlobeNewsWire

BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate muta...

1 year ago - GlobeNewsWire

While IPOs allow companies to tap into capital markets, going public provides liquidity to early-stage investors seeking to unload stock positions.

Other stocks mentioned: FREQ, VIE, VIR
1 year ago - The Motley Fool

The drug candidate is in phase 3 trials as a treatment of myelodysplastic syndrome (MDS), which often leads to blood and bone marrow cancers.

1 year ago - The Motley Fool

BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutan...

1 year ago - GlobeNewsWire

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

Other stocks mentioned: APLT, BNTX, GKOS, INMD, KRTX, NXTC, PLMR ...
1 year ago - The Motley Fool

BOSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Lead investigators from US and French Phase Ib/II clinical trials of APR-246 and Azacitidine (AZA) in patients with TP53 mutant MDS and AML, presented positiv...

1 year ago - GlobeNewsWire

BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate muta...

1 year ago - GlobeNewsWire

Aprea Therapeutics Inc (NASDAQ: APRE) shares cooled a bit Tuesday after getting off to a hot start on the market following an Oct.

1 year ago - Benzinga

BOSTON, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutan...

1 year ago - GlobeNewsWire

Three biotech companies successfully completed IPOs last week. Would investors have been better off buying shares in the open market?

Other stocks mentioned: FREQ, VIE
1 year ago - The Motley Fool

Aprea Therapeutics, Inc. (NASDAQ: APRE) made its public debut Thursday morning, opening at $15.46 after being priced at $15 per share.

1 year ago - Benzinga

Aprea Therapeutics Inc. APRE, +11.00% got off to a positive start as a public company Thursday, as the first trade of the cancer treatment developer's stock was 3.1% above its $15 initial public offerin...

1 year ago - Market Watch

About APRE

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung ca... [Read more...]

Industry
Biotechnology
IPO Date
Oct 3, 2019
Stock Exchange
NASDAQ
Ticker Symbol
APRE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for APRE stock is "Hold." The 12-month stock price forecast is 7.50, which is an increase of 85.19% from the latest price.

Price Target
$7.50
(85.19% upside)
Analyst Consensus: Hold